REFERENCE
Novartis.Novartis announces initiative to improve access to state-of-the-art anti-malarial treatment Coartem (Rm). Media Release: 29 Sep 2006. Available from: URL: http://www.novartis.com
Rights and permissions
About this article
Cite this article
Novartis has reduced the average price of its antimalarial drug Coartem [artemether/lumefantrine] from an average $US1.57 to $US1.00 per treatment. Pharmacoecon. Outcomes News 514, 11 (2006). https://doi.org/10.2165/00151234-200605140-00032
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605140-00032